News and Events

News

All categories

Earnings

Press Release

All years

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank

January 11, 2021

Affimed Announces Pipeline and Business Update

January 7, 2021

Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-positive Lymphoma with Cutaneous Presentation

December 7, 2020

Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD’s anti-PD-1 therapy KEYTRUDA^® (pembrolizumab) in Blood

November 19, 2020

Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress

November 10, 2020

Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Innate Cell Engagers (ICE^® ) for Multiple Cancer Targets

November 9, 2020

New Preclinical Data being Presented at SITC Underscore Promising Combinations of Affimed’s AFM13 and Cytokine-Activated Natural Killer Cells

November 9, 2020

Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapies

November 5, 2020

Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting and Exposition

November 4, 2020

Affimed to Present at Upcoming Investor Conferences

November 4, 2020

Events

All

Scientific

Investors

09Dec

ASH Annual Meeting

December 9 - 12, 2023 (San Diego, USA)

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank

Affimed Announces Pipeline and Business Update

Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-positive Lymphoma with Cutaneous Presentation

Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD’s anti-PD-1 therapy KEYTRUDA^® (pembrolizumab) in Blood

Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress

Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Innate Cell Engagers (ICE^® ) for Multiple Cancer Targets

New Preclinical Data being Presented at SITC Underscore Promising Combinations of Affimed’s AFM13 and Cytokine-Activated Natural Killer Cells

Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapies

Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting and Exposition

Affimed to Present at Upcoming Investor Conferences

Events

ASH Annual Meeting